Healthtech is changing fast. To succeed, leaders must connect science, business, and patient needs. My career has been about building those bridges—turning research into real-world solutions that improve care and grow companies.
I have spent more than 20 years at this intersection. My career began in chemistry and toxicology research and grew into executive roles leading multimillion-dollar healthcare enterprises. Along the way, I’ve seen that the best leaders are translators. They take complex science and shape it into solutions that scale, reach patients, and make business sense.
From Scientist to Executive
My foundation was built in the lab. I studied mechanistic toxicology, biomarkers, and diagnostics. That training taught me two key lessons: respect for data integrity and the power of asking the right questions.
When I moved into executive roles, I found those lessons carried over. Business, like science, is a series of experiments. You form a hypothesis, test it, measure results, and adjust. Leaders who use evidence, not guesswork, are better prepared to manage uncertainty and guide teams through change.
Leading Growth at Select Laboratory Partners
At Select Laboratory Partners, where I served as President and COO, I applied this approach to scale the company from a regional lab into a national enterprise. We grew five subsidiaries into more than $35 million in annual revenue.
Some of the most important steps included:
Bringing new diagnostic technologies and FDA-cleared assays to market.
Launching AI-enabled patient portals that improved engagement and access to health data.
Negotiating multi-year contracts with national clients, with governance frameworks to ensure performance.
Building reimbursement strategies that aligned with payer expectations and secured long-term viability.
These efforts expanded our reach into 25 states and positioned the company as a trusted partner in diagnostics.
Science That Moves Beyond the Bench
Healthtech innovation begins in research, but it only matters when it reaches patients. My work in biomarkers spans immune health, inflammation cascades, oxidative stress, cardiometabolic disease, rare disorders, and women’s health.
These fields are complex and often underserved. By focusing on translational science—turning discoveries into diagnostics that clinicians can use—we can close gaps in care, shorten delays in diagnosis, and improve patient outcomes.
Balancing Vision and Execution
A challenge in healthtech is balancing bold vision with disciplined execution. I have seen promising technologies stall, not because of bad science, but because of weak business models or unclear reimbursement paths.
My leadership style supports creativity and vision, but grounds them in operational discipline. Consulting with startups has reinforced this lesson. Innovation thrives when paired with governance, compliance, and financial strength.
Why Boards Matter
Boards of directors are critical to this balance. They provide the guardrails that keep innovation responsible and sustainable. Boards that engage with both the science and the business side create the conditions for real impact. They drive accountability, ensure strategy stays patient-focused, and help organizations build long-term value.
Looking Forward
The future of healthtech will be defined by translation, not just discovery. AI, biomarkers, and personalized medicine all hold promise—but only if leaders can bridge the gap between lab and marketplace.
That has been the theme of my career. I believe better diagnostics lead to better lives. And I believe that strong leadership, informed by both science and business, is the key to unlocking that future.
